合作邀请函 | 沙利文即将发布《2026全球ECM行业白皮书》

In recent years, under the combined influence of technological innovation and clinical needs in regenerative medicine, the extracellular matrix (ExtracellularMatrix,ECM) is accelerating its transition from basic research to clinical application and industrial production.

On the technical side, continuous breakthroughs in decellularization processes have significantly addressed the core conflict between natural biomaterials"antigen removal and structural preservation"; synthetic biology technologies enable the prevention of immunogenicity at the source through recombinant expression, combined with engineered cross-linking modifications, allowing the degradation and tissue regeneration rates of materials to be coordinated and controlled, thus establishing a solid technical foundation for large-scale production and full-lifecycle quality control.

On the application side,ECM-based bionic three-dimensional in vitro microenvironments are deeply integrated with biological response systems, continuously expanding their applications in clinical medicine, medical aesthetics, and cutting-edge life sciences.

Currently, with the increasingly clear regulatory pathways in both global and Chinese markets, the surge in demand for healing wounds with complex complications, and the explosion in Dual Carbon & New Energy market for regenerative medical aesthetics, the ChineseECM industry is in a critical window period transitioning from "laboratory production" to "standardized, scaled, commercialized, and compliant applications." How to seize development opportunities during the iterative process of technology and improving regulatory science has become a major strategic issue that R&D companies, research institutions, and investors are focusing on together.

Based on long-term tracking and in-depth research in life sciences and cutting-edge medicine, Frost & Sullivan (Frost & Sullivan, hereinafter referred to as "Frost & Sullivan") plans to officially release the "2026 Global ECM Industry White Paper" in 2026 and invites outstanding companies, research institutions, and industry partners in the industry to participate, working together to promote the standardization and innovative development of the Chinese ECM industry.

Research Content

This white paper will systematically reviewthe current status and future trends of the ECM industry, focusing on ECM technology iteration, core application scenarios, driving factors, industry competition landscape, and regulatory and access policies, providing a structural understanding of the overall industry pattern and offering professional references for industry participants.

First,ECM technology path

The report will deeply analyze the balance and breakthroughs in traditional decellularization processes (dECM) between "antigen removal and structural preservation," and in conjunction with synthetic biology advancements, discuss the quality control consistency of recombinant ECM proteins, thereby clarifying the industrial path for ECM materials to evolve toward high purity and low risk.

Second,ECM core application scenarios

The research will extend beyond surgical wound repair and tissue engineering patches to include regenerative medical aesthetics injections, as well as in vitro bionic tumor microenvironments and high-throughput organ-on-a-chip drug screening in cutting-edge fields.

·Surgical wound repair:ECM materials promote tissue regeneration and reduce scar formation;

·Tissue engineering patches:ECM materials are used to repair or replace damaged tissues, providing mechanical support and cell growth scaffolds;

·Medical aesthetics injection products:ECM materials activate fibroblasts to induce collagen regeneration;

·Construction of in vitro bionic tumor microenvironmentSimulating the in vivoECM environment, used for studying tumor invasion, metastasis, and drug response;

·High-throughput organ-on-a-chip drug screeningUsingECM hydrogels to culture organ-on-a-chip, improving the accuracy and efficiency of drug screening.

Third,Driving factors for ECM industry development

The white paper will focus on analyzingmultiple macro drivers of the ECM industry: population aging creates a demand for chronic difficult-to-heal wounds, consumption upgrades drive growth in regenerative medical aesthetics and high-end repair markets, mature underlying biotechnological equipment provides benefits for large-scale production, clearer regulatory science paths release compliance incentives, breakthroughs in synthetic biology and engineered cross-linking technologies provide opportunities for product expansion, and continuous inflow of global capital accelerates industrial integration.

Fourth,Global competition landscape of the ECM industry

The report will analyze the multi-center clinical data accumulation of European and American companies, as well as the differentiated industrial advantages built by Chinese companies in the recombinant protein sector through synthetic biology, presenting a comprehensive view of the competitive and cooperative situation in the global ecosystem.

第五，ECM regulation and access policies

The white paper will systematically review theECM implant-level product regulations and access policies of major global countries and regions such as China, the United States, and the European Union, providing authoritative scientific references for the compliant application of advanced materials and cross-border BD licensing.

第六，Capital performance and representative companies in the ECM industry

The report will analyze thecapital market performance in the ECM sector globally and in China, including financing situations of R&D companies, licensing transactions, and mergers and acquisitions events. Finally, the white paper will include a special section on companies, providing in-depth introductions to domestic and foreign ECM R&D companies, covering company development history, business layout, technical advantages, and latest research progress, highlighting the differentiated positioning and core competitiveness of companies within the industry panorama.

Frost & Sullivan invites outstanding companies in the ECM field to participate in this white paper, working together with multiple parties in the industry chain to engage in research and release processes, forming a rational expression and consensus accumulation regarding industry development under a professional analysis framework, and jointly promoting the standardization and sustainable development of the Chinese ECM industry.

Release Highlights

1.Global release of the white paper to enhance industry visibility through technical strength

Asa systematic research achievement in the ECM field, this white paper will be widely released through Frost & Sullivan's official website, global media networks, and life science vertical channels. The report will deeply present the core advantages of participating companies, focusing on the innovation of technical platforms, depth of product pipeline, key data, regulatory milestones, and large-scale production capabilities. Through differentiated presentation, it will help the market establish a clear understanding of companies' technical and industrial capabilities, enhance industry influence and brand credibility, and provide a platform for authoritative voice and concentrated display for companies.

The English version will also be published simultaneously in world-renowned news agencies (such as The Associated Press), mainstream financial media (such as Yahoo Finance), North American financial media and websites (such as Business Insider, Dow Jones Market Watch,Benzinga, Wall Street Insider, etc.), as well as global regional media channels, further expanding the brand visibility of companies in the international market and helping Chinese ECM companies promote global brand building and technical cooperation.

2.Linking the industrial ecosystem and expanding cooperation network

The white paper will establish a communication platform connectingmultiple entities in the ECM industry chain, promoting deep interaction and resource matching among enterprises with different positions. R&D companies, manufacturing companies, etc. can present their businesses differently, facilitating complementary integration of R&D and production capabilities through precise matching, enhancing mutual understanding with investment institutions and industry partners, and creating more opportunities for technical collaboration, resource integration, and business expansion.

3.Strengthening professional positioning and enhancing brand recognition

Based on the systematic analysis ofECM technology, commercial transformation paths, and regulatory science by the white paper, the professional expertise of participating companies will be objectively presented. Through the in-depth presentation of research content, the recognition and influence of companies in terms of technical platforms, product progress, or production capabilities will be enhanced, solidifying their differentiated market positioning.

4.Connecting with diverse capital and seizing strategic opportunities

With Frost & Sullivan's network of investment institutions and industry partners in the life sciences field, the release of the white paper will effectively increase company visibility and connect with various types of capital. Early R&D companies can reach VCs/PE that focus on the innovation of technical platforms;Clinical-stage companies can connect with industry capital and BigPharmaBD that focus on later clinical assets and commercial potential; large-scale manufacturing companies can attract strategic investors interested in manufacturing capabilities. A communication bridge will be established between companies and diverse capital, enabling them to take an active position in financing, technology licensing, mergers and acquisitions, and strategic cooperation.

5.Deepening long-term cooperation and creating industry value together

Based on the deep communication established through the white paper cooperation, Frost & Sullivan can explore multiple collaborative directions with participating companies, including brand promotion, investment and financing consulting, growth strategy, etc. The two sides are expected to establish a long-term partnership based on this cooperation, jointly addressing industry changes and promoting the high-quality development of the ECM industry.